TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.

Shengli Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.